Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
7
Neutral
4
Bullish
3
Bearish
21
Neutral
4
Bullish
21
Bearish
14
Neutral
0
Bullish
18
Discovery themes featuring this stock
Checkpoint Trends Limited, previously known as Rubra Medicaments Ltd, was established in 1991 and is now involved in trading and consultancy services.
The company has transitioned from manufacturing pharmaceutical formulations to offering a broad array of consulting services across various sectors.
Checkpoint Trends Limited is actively exploring alternative business opportunities, indicating a shift in its strategic direction to diversify its offerings.
The company's operations now emphasize providing high-quality consulting services at competitive prices, showcasing its flexibility in adapting to market demands.
Pharmaceuticals & Biotechnology
Pharmaceuticals
25 Cr
Low Risk
12.5
33.9
-0.0
12.9
144.40
16.06
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
24.00 | 28 Cr | 139.00 | 1.97 | 0.00 | 1.76 | 1.92 | 1.23 | ||
35.25 | 27 Cr | -21.32 | 3.05 | 0.00 | -13.06 | 39.56 | -5.20 | ||
44.25 | 27 Cr | -106.68 | 0.00 | 0.00 | 20.74 | -104.17 | -21.01 | ||
18.00 | 26 Cr | 4.71 | 0.78 | 0.00 | 15.59 | 20.51 | 12.72 | ||
46.45 | 25 Cr | 12.47 | 12.91 | 0.00 | 73.94 | 98.45 | 1.45 | ||
81.90 | 22 Cr | 25.17 | 1.99 | 0.00 | 8.65 | 10.56 | 6.11 | ||
12.45 | 22 Cr | 26.51 | 0.71 | 0.00 | 2.67 | 6.38 | 0.70 | ||
| Median: 7 Co. | — | 35.25 | 26 Cr | 12.47 | 1.97 | 0.00 | 8.65 | 10.56 | 1.23 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Centuple Global Ltd (CHECKPOINT) is currently trading at 46.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Checkpoint Trends Limited, previously known as Rubra Medicaments Ltd, was established in 1991 and is now involved in trading and consultancy services. The company has transitioned from manufacturing pharmaceutical formulations to offering a broad array of consulting services across various sectors. Checkpoint Trends Limited is actively exploring alternative business opportunities, indicating a shift in its strategic direction to diversify its offerings. The company's operations now emphasize providing high-quality consulting services at competitive prices, showcasing its flexibility in adapting to market demands.
Over the past 52 weeks, Centuple Global Ltd has traded between a low of ₹16.06 and a high of ₹144.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Centuple Global Ltd has a market capitalization of approximately 25.43. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Centuple Global Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 12.47 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 25.43 Cr, Centuple Global Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Centuple Global Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Centuple Global Ltd is 12.47. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Director Resignation
Centuple Global accepted resignation of Mr. Kumar Anubhav Upadhyay (DIN:09519842) as Whole‑time Director effective May 26, 2026, citing pre‑occupation/personal commitments (resignation letter cites better prospects); he is DP in two LLPs.
Director appointments
EGM on Jun 18, 2026 (09:00 AM via VC/OAVM) to approve appointment of Mr. Gaurav Kaushik and Mr. Ashish Jain as independent directors (Mar 18, 2026–Mar 17, 2031) and M/s Payal Dhamecha & Associates as secretarial auditor (FY2025‑26 to FY2029‑30).
Board Meeting - Audited Results
Centuple Global Ltd will meet on May 30, 2026 to consider and approve audited standalone financial results for the quarter and year ended March 31, 2026, take on record the auditor's report, adopt deviation statement and appoint an internal auditor.
Board meeting outcome
Board approved regularisation of Mr. Gaurav Kaushik and Mr. Ashish Jain as Non‑Executive Independent Directors (subject to members' approval), change of secretarial auditor, set EGM on 18 Jun 2026 and e‑voting schedule (15–17 Jun).
Board Meeting Outcome
Board called an EGM on 18 Jun 2026 to seek shareholder approval to regularise Mr. Gaurav Kaushik and Mr. Ashish Jain as Non‑Executive Independent Directors and to appoint a new secretarial auditor; e‑voting set for 15–17 Jun and NVB & Associates appointed scrutinizer.
Board Meeting Notice
Board meeting on May 30, 2026 to approve audited standalone financial results for quarter and year ended Mar 31, 2026, take on record auditor's report, adopt deviation statement, appoint internal auditor; trading window closed until 48 hrs after results.
